Abstract
Background and Aims: Insulin degrading enzyme (IDE) contributes to the degradation processes of insulin and Aβ. We aimed to investigate the role of IDE in type 2 diabetes patients with mild cognitive impairment (MCI).
Methods: A total of 146 individuals with type 2 diabetes were enrolled and divided into two groups according to the Montreal Cognitive Assessment (MoCA) score. Demographic characteristics, cognitive function and serum IDE level were examined.
Results: There were 75 patients with MCI and 71 patients without MCI. Diabetic patients with MCI had a higher serum level of IDE compared with the control group (p < 0.001). Among patients with MCI, serum IDE level was positively correlated with the MoCA score (r = 0.839; p < 0.001). Correlation analysis demonstrated that IDE was positively correlated with MoCA score (r = 0.815; p < 0.001) but negatively correlated with the Trail Making Test-B (r = −0.413; p < 0.001), fasting blood-glucose (r = −0.372; p < 0.001), glycosylated hemoglobin (r = −0.214; p = 0.015), homeostasis model of assessment for insulin resistance (r = −0.560; p < 0.001) and the mean amplitude of glycemic excursions (r = −0.551; p < 0.001) in all subjects. In logistic regression analysis for MCI, IDE (p = 0.010) was an independent variable, after adjusting for age, sex, education, liver function, kidney function, and lipid levels.
Conclusion: This study demonstrated a greater likelihood of MCI with decreasing serum IDE in patients with type 2 diabetes.
Keywords: Homeostasis model of assessment for insulin resistance, insulin degrading enzyme, mild cognitive impairment, the mean amplitude of glycemic excursions, the Trail Making Test-B, Type 2 diabetes.
Current Alzheimer Research
Title:Serum Insulin Degrading Enzyme Level and Other Factors in Type 2 Diabetic Patients with Mild Cognitive Impairment
Volume: 13 Issue: 12
Author(s): Jie Sun, Wenqing Xia, Rongrong Cai, Pin Wang, Rong Huang, Haixia Sun, Sai Tian, Xue Dong and Shaohua Wang
Affiliation:
Keywords: Homeostasis model of assessment for insulin resistance, insulin degrading enzyme, mild cognitive impairment, the mean amplitude of glycemic excursions, the Trail Making Test-B, Type 2 diabetes.
Abstract: Background and Aims: Insulin degrading enzyme (IDE) contributes to the degradation processes of insulin and Aβ. We aimed to investigate the role of IDE in type 2 diabetes patients with mild cognitive impairment (MCI).
Methods: A total of 146 individuals with type 2 diabetes were enrolled and divided into two groups according to the Montreal Cognitive Assessment (MoCA) score. Demographic characteristics, cognitive function and serum IDE level were examined.
Results: There were 75 patients with MCI and 71 patients without MCI. Diabetic patients with MCI had a higher serum level of IDE compared with the control group (p < 0.001). Among patients with MCI, serum IDE level was positively correlated with the MoCA score (r = 0.839; p < 0.001). Correlation analysis demonstrated that IDE was positively correlated with MoCA score (r = 0.815; p < 0.001) but negatively correlated with the Trail Making Test-B (r = −0.413; p < 0.001), fasting blood-glucose (r = −0.372; p < 0.001), glycosylated hemoglobin (r = −0.214; p = 0.015), homeostasis model of assessment for insulin resistance (r = −0.560; p < 0.001) and the mean amplitude of glycemic excursions (r = −0.551; p < 0.001) in all subjects. In logistic regression analysis for MCI, IDE (p = 0.010) was an independent variable, after adjusting for age, sex, education, liver function, kidney function, and lipid levels.
Conclusion: This study demonstrated a greater likelihood of MCI with decreasing serum IDE in patients with type 2 diabetes.
Export Options
About this article
Cite this article as:
Sun Jie, Xia Wenqing, Cai Rongrong, Wang Pin, Huang Rong, Sun Haixia, Tian Sai, Dong Xue and Wang Shaohua, Serum Insulin Degrading Enzyme Level and Other Factors in Type 2 Diabetic Patients with Mild Cognitive Impairment, Current Alzheimer Research 2016; 13 (12) . https://dx.doi.org/10.2174/1567205013666160615091043
DOI https://dx.doi.org/10.2174/1567205013666160615091043 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mexiletine Metabolites: A Review
Current Medicinal Chemistry Pyridoxal 5-Phosphate Enzymes as Targets for Therapeutic Agents
Current Medicinal Chemistry Editorial (Thematic Issue: Measurements of ABC Transporters at the Blood-Brain Barrier: Novel Methods and Applications)
Current Pharmaceutical Design Neonatal Diabetes: Applying Molecular Biology to Patient Care
Current Pediatric Reviews Drug Repurposing Approaches: Existing Leads for Novel Threats and Drug Targets
Current Protein & Peptide Science Familial Mediterranean Fever
Current Rheumatology Reviews Lafora Progressive Myoclonus Epilepsy: Recent Insights into Cell Degeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Area, Age and Gender Dependence of the Nucleoside System in the Brain: a Review of Current Literature
Current Topics in Medicinal Chemistry Imidazoline Receptors, Novel Agents and Therapeutic Potential
Cardiovascular & Hematological Agents in Medicinal Chemistry Epigenetics in Vascular Disease – Therapeutic Potential of New Agents
Current Vascular Pharmacology Interferon-γ-Induced Neurotoxicity of Human Astrocytes
CNS & Neurological Disorders - Drug Targets Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation
Current Drug Safety Comparison of HPLC-DAD and UPLC-MS/MS in Monitoring Serum Concentration of Lamotrigine
Current Pharmaceutical Analysis Molecular and Biochemical Features in Alzheimers Disease
Current Pharmaceutical Design Consensus Guideline Based Therapeutic Drug Monitoring (TDM) in Psychiatry and Neurology
Current Drug Delivery Benzodiazepines and Sleep Architecture: A Systematic Review
CNS & Neurological Disorders - Drug Targets VEGF Signaling Regulates Cofilin and the Arp2/3-complex within the Axonal Growth Cone
Current Neurovascular Research The Effects of Locus Coeruleus and Norepinephrine in Methamphetamine Toxicity
Current Neuropharmacology Organotypic Brain Slices of ADULT Transgenic Mice: A Tool to Study Alzheimer’s Disease
Current Alzheimer Research Treating Rapid Cycling Bipolar Disorder with Novel Medications
Current Psychiatry Reviews